SCHEMBL7072330

SCHEMBL7072330

O=c1[nH][nH]c(=O)c2cc(Nc3ccccc3)ccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 2/20 0.58
▸ ALDH1A1 P00352 6/20 0.48
▸ MAPT P10636 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ AR P10275 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ HSD17B10 Q99714 4/20 0.48
▸ TSHR P16473 3/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ PTGS1 P23219 1/20 0.48
▸ SLC6A2 P23975 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ PTGS2 P35354 1/20 0.48
▸ HTR2B P41595 1/20 0.48
▸ ERCC1 P07992 1/20 0.48
▸ DNASE1 P24855 1/20 0.48
▸ FEN1 P39748 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9413538 0.81 BRAF (0.76) BRAFALDH1A1MAPTMEN1AR
SCHEMBL25835159 0.80 ERCC1 (0.57) ALDH1A1MAPTMEN1KMT2AHSD17B10
SCHEMBL23087681 0.76 PRMT5 (0.61) —
SCHEMBL1551938 0.76 ALDH1A1 (0.62) ALDH1A1MAPTMEN1ARKMT2A
SCHEMBL6517435 0.75 AURKA (0.67) ALDH1A1MAPTERCC1DNASE1FEN1
SCHEMBL3277310 0.75 HSD17B10 (0.46) BRAFALDH1A1MAPTHSD17B10TDP1
SCHEMBL7070839 0.75 KDM4E (0.50) BRAFARHSD17B10TDP1KDM4E
SCHEMBL25835280 0.73 ERCC1 (0.50) ALDH1A1MEN1KMT2AHSD17B10TDP1
SCHEMBL8691865 0.72 KDM4E (0.43) BRAFALDH1A1HSD17B10LMNAKDM4E
SCHEMBL29922938 0.71 ALDH1A1 (0.54) ALDH1A1MAPTMEN1ARKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1315497-A2 AMINO DERIVATIVES OF 2,3-DIHYDROPHTALAZINE-1,4-DIONE AS IMMUNOCORRECTING AGENTS Medinkor ZMM AG (CH) 2003-06-04 — — EP claimed
WO-2002009681-A2 A METHOD FOR CORRECTING THE IMMUNE SYSTEM OF LIVE BODY MEDINKOR ZMM AG (CH) 2002-02-07 — — WO claimed
US-20030195183-A1 Method for correcting immune system of live body ZHILOV VALERII KHAZHUMURATOVIC (RU) 2003-10-16 — — US disclosed
EP-1315497-A2 AMINO DERIVATIVES OF 2,3-DIHYDROPHTALAZINE-1,4-DIONE AS IMMUNOCORRECTING AGENTS Medinkor ZMM AG (CH) 2003-06-04 — — EP disclosed
WO-2002009681-A2 A METHOD FOR CORRECTING THE IMMUNE SYSTEM OF LIVE BODY MEDINKOR ZMM AG (CH) 2002-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195183-A1 Method for correcting immune system of live body IL15, IL5, IL2 BRAF 4798/4885ALDH1A1 151/4885MAPT 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback